NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Price Target & More

$17.56 -0.29 (-1.62 %)

(As of 04/24/2018 04:00 PM ET)

Previous Close$17.56

Today's Range$17.49 - $18.39

52-Week Range$10.85 - $33.82

Volume11.73 million shs

Average Volume14.59 million shs

Market Capitalization$18.12 billion

P/E Ratio4.47

Dividend Yield2.43%

Beta0.67

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:TEVA

CUSIPN/A

Webwww.tevapharm.com

Phone972-3926-7267

Debt

Debt-to-Equity Ratio1.91%

Current Ratio0.86%

Quick Ratio0.58%

Price-To-Earnings

Trailing P/E Ratio4.47

Forward P/E Ratio7.63

P/E Growth1.55

Sales & Book Value

Annual Sales$22.39 billion

Price / Sales0.80

Cash Flow$6.1614 per share

Price / Cash2.85

Book Value$14.86 per share

Price / Book1.18

Profitability

EPS (Most Recent Fiscal Year)$3.93

Net Income$-16,265,000,000.00

Net Margins-72.66%

Return on Equity16.43%

Return on Assets4.91%

Miscellaneous

Employees51,792

Outstanding Shares1,016,880,000

How to Become a New Pot Stock Millionaire

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries declared a quarterly dividend on Thursday, November 2nd. Investors of record on Tuesday, November 28th will be given a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a yield of 1.94%. The ex-dividend date of this dividend is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries (NYSE:TEVA) posted its quarterly earnings data on Thursday, February, 8th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.14. The firm had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business's revenue was down 15.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.38 earnings per share. View Teva Pharmaceutical Industries' Earnings History.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY18 earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of $2.25-2.50 for the period, compared to the Thomson Reuters consensus estimate of $2.99. The company issued revenue guidance of $18.3-18.8 billion, compared to the consensus revenue estimate of $19.36 billion.

What price target have analysts set for TEVA?

27 equities research analysts have issued twelve-month price objectives for Teva Pharmaceutical Industries' shares. Their predictions range from $11.00 to $41.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $20.0192 in the next twelve months. View Analyst Ratings for Teva Pharmaceutical Industries.

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:

1. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
2. According to Zacks Investment Research, "Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva’s shares have underperformed the generic industry in the past one year. Mylan’s earlier-than-expected launch of the first generic version of the 40-mg strength of Copaxone was a major setback for Teva. Though Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years, a clear path to growth is not visible. Estimates have gone up ahead of the company’s Q4 earnings release due to expected cost savings from the restructuring plan. Teva has a negative record of earnings surprises. " (1/12/2018)
3. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)
4. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a drop in short interest during the month of April. As of April 13th, there was short interest totalling 55,840,620 shares, a drop of 6.0% from the March 30th total of 59,397,239 shares. Based on an average trading volume of 8,749,778 shares, the days-to-cover ratio is presently 6.4 days. Approximately 5.5% of the shares of the company are sold short.

Who are some of Teva Pharmaceutical Industries' key competitors?

Some companies that are related to Teva Pharmaceutical Industries include Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Grifols (GRFS) and Ono Pharmaceutical (OPHLF).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:

Mr. Michael McClellan, Exec. VP & CFO (Age 47)
Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 60)
Mr. Mark Sabag, Exec. VP of Global HR (Age 47)
Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 56)
Mr. Kåre Schultz, Pres, Chief Exec. Officer & Director (Age 57)

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

News stories about TEVA stock have been trending somewhat positive on Tuesday, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a news impact score of 0.21 on Accern's scale. They also gave news coverage about the company an impact score of 43.94 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional investors include ALLERGAN PLC (3.90%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $17.56.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $18.12 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]

MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		972 (Vote Outperform)
Underperform Votes:		848 (Vote Underperform)
Total Votes:		1,820

MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

27 Wall Street analysts have issued ratings and price targets for Teva Pharmaceutical Industries in the last 12 months. Their average twelve-month price target is $20.0192, suggesting that the stock has a possible upside of 14.00%. The high price target for TEVA is $41.00 and the low price target for TEVA is $11.00. There are currently 7 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	1.96	1.96	2.07	2.08
Ratings Breakdown:	7 Sell Rating(s) 14 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	7 Sell Rating(s) 14 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	5 Sell Rating(s) 16 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	4 Sell Rating(s) 16 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$20.0192	$20.7963	$21.2654	$26.1560
Price Target Upside:	14.00% upside	16.12% upside	3.36% upside	87.77% upside

Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History

Price Target History for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/22/2018	Wells Fargo	Set Price Target	Sell	$17.00	Low
4/20/2018	Mizuho	Reiterated Rating	Buy	$27.00	Low
4/4/2018	Credit Suisse Group	Set Price Target	Buy	$23.00	High
3/26/2018	Royal Bank of Canada	Reiterated Rating	Hold	$16.00	Low
3/20/2018	Jefferies Group	Initiated Coverage	Hold -> Hold	$19.00	Medium
3/1/2018	Maxim Group	Reiterated Rating	Hold		Medium
2/9/2018	Bank of America	Lower Price Target	Underperform -> Underperform	$17.00 -> $16.00	Low
2/9/2018	Leerink Swann	Lower Price Target	Underweight -> Underperform	$17.00 -> $16.00	High
2/9/2018	Deutsche Bank	Lower Price Target	Hold -> Hold	$20.00 -> $18.00	Medium
2/9/2018	Gabelli	Downgrade	Buy -> Hold	$19.00	Medium
2/9/2018	Piper Jaffray	Downgrade	Neutral -> Underweight	$11.00	Medium
2/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$18.00	Medium
2/8/2018	Oppenheimer	Reiterated Rating	Hold		Medium
2/2/2018	BTIG Research	Downgrade	Neutral -> Sell	$17.00	Low
1/25/2018	Susquehanna Bancshares	Reiterated Rating	Positive -> Positive	$22.00 -> $24.00	Medium
1/11/2018	Goldman Sachs	Boost Price Target	Buy	$20.00 -> $25.00	High
1/4/2018	Citigroup	Upgrade	Neutral -> Buy	$24.00	Low
12/18/2017	UBS	Set Price Target	Hold	$12.00 -> $20.00	Low
12/15/2017	Morgan Stanley	Upgrade	Underweight -> Equal Weight	$18.00	Medium
12/12/2017	Guggenheim	Initiated Coverage	Neutral -> Neutral	$16.00	High
11/13/2017	JPMorgan Chase	Downgrade	Neutral -> Underweight	$11.48 -> $11.00	N/A
10/25/2017	Evercore ISI	Set Price Target	Buy	$38.00	N/A
10/20/2017	Barclays	Set Price Target	Hold	$21.00 -> $19.00	N/A
10/4/2017	Cowen	Reiterated Rating	Market Perform	$30.00 -> $18.00	N/A
9/21/2017	Sanford C. Bernstein	Lower Price Target	Mkt Perform -> Market Perform	$28.00 -> $20.00	Low
9/6/2017	JMP Securities	Boost Price Target	Underperform	$13.00 -> $14.00	Low
8/3/2017	CIBC	Reiterated Rating	Outperform -> Market Perform		High
2/28/2017	Argus	Downgrade	Buy -> Hold	$59.35 -> $31.90	N/A
9/29/2016	OTR Global	Initiated Coverage	Positive		N/A

(Data available from 4/24/2016 forward)

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart

Earnings by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates

2018 EPS Consensus Estimate: $2.19

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.58	$0.63	$0.61
Q2 2018	2	$0.52	$0.59	$0.56
Q3 2018	2	$0.49	$0.55	$0.52
Q4 2018	2	$0.50	$0.51	$0.51

Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/3/2018		$0.63					N/A
2/8/2018	Q4 17	$0.77	$0.91	$5.2870 billion	$5.4590 billion	View	Listen
11/2/2017	Q3 2017	$1.03	$0.95	$5.6065 billion	$5.61 billion	View	N/A
8/3/2017	6/30/2017	$1.06	$0.99	$5.7168 billion	$5.6860 billion	View	Listen
5/11/2017	Q1 17	$1.06	$1.06	$5.6885 billion	$5.63 billion	View	N/A
2/13/2017	Q416	$1.36	$1.38	$6.26 billion	$6.25 billion	View	N/A
11/15/2016	Q316	$1.29	$1.31	$5.7132 billion	$5.56 billion	View	N/A
8/4/2016	Q216	$1.20	$1.25	$4.86 billion	$5.00 billion	View	N/A
5/9/2016	Q116	$1.17	$1.20	$4.78 billion	$4.81 billion	View	N/A
2/11/2016	Q415	$1.29	$1.28	$4.83 billion	$4.88 billion	View	Listen
10/29/2015	Q315	$1.28	$1.35	$4.75 billion	$4.80 billion	View	Listen
7/30/2015	Q215	$1.31	$1.43	$4.90 billion	$4.97 billion	View	Listen
4/30/2015	Q115	$1.26	$1.36	$4.84 billion	$5.00 billion	View	N/A
2/5/2015	Q414	$1.31	$1.31	$5.17 billion	$5.17 billion	View	N/A
10/30/2014	Q314	$1.23	$1.32	$5.09 billion	$5.06 billion	View	N/A
7/31/2014	Q214	$1.21	$1.23	$5.08 billion	$5.00 billion	View	N/A
5/1/2014	Q114	$1.22	$1.22	$5.11 million	$5.00 billion	View	N/A
2/6/2014	Q413	$1.26	$1.42	$5.19 billion	$5.40 billion	View	N/A
10/31/2013	Q313	$1.26	$1.27	$5.00 billion	$5.0590 billion	View	N/A
8/1/2013	Q213	$1.20	$1.20	$4.94 billion	$4.90 billion	View	N/A
5/2/2013	Q113	$1.10	$1.12	$4.85 billion	$4.90 billion	View	N/A
2/7/2013	Q412	$1.33	$1.32	$5.26 billion	$5.20 billion	View	N/A
11/1/2012	Q312	$1.25	$1.28	$5.08 billion	$5.00 billion	View	N/A
8/2/2012		$1.28	$1.28			View	N/A
5/9/2012		$1.44	$1.47			View	N/A
2/15/2012		$1.58	$1.59			View	N/A
11/2/2011		$1.22	$1.25			View	N/A
7/27/2011		$1.08	$1.10			View	N/A
5/11/2011		$1.03	$1.04			View	N/A
2/8/2011		$1.28	$1.25			View	N/A
11/2/2010	Q3 2010	$1.27	$1.30			View	N/A
7/26/2010	Q2 2010	$1.04	$1.08			View	N/A
5/4/2010	Q1 2010	$0.89	$0.92			View	N/A
2/16/2010	Q4 2009	$0.95	$0.94			View	N/A
11/3/2009	Q3 2009	$0.88	$0.89			View	N/A
7/28/2009	Q2 2009	$0.80	$0.83			View	N/A
5/5/2009	Q1 2009	$0.67	$0.72			View	N/A
2/17/2009	Q4 2008	$0.73	$0.76			View	N/A
11/6/2008	Q3 2008	$0.69	$0.72			View	N/A
7/29/2008	Q2 2008	$0.64	$0.65			View	N/A
5/6/2008	Q1 2008	$0.63	$0.64			View	N/A
2/12/2008	Q4 2007	$0.66	$0.69			View	N/A

(Earnings results data provided by Zacks Investment Research)

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information

Teva Pharmaceutical Industries pays an annual dividend of $0.43 per share, with a dividend yield of 2.45%. TEVA's most recent quarterly dividend payment was Tuesday, December 12. Teva Pharmaceutical Industries pays out 10.94% of its earnings out as a dividend.

Most Recent Dividend:	12/12/2017
Annual Dividend:	$0.43
Dividend Yield:	2.45%
Dividend Growth:	-14.40% (3 Year Average)
Payout Ratio:	10.94% (Trailing 12 Months of Earnings) 18.70% (Based on This Year's Estimates) 17.48% (Based on Next Year's Estimates)
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
11/2/2017	quarterly	$0.0850	2.74%	11/27/2017	11/28/2017	12/12/2017
8/7/2017	quarterly	$0.0850	1.83%	8/25/2017	8/29/2017	9/14/2017
5/11/2017	quarterly	$0.34	4.28%	6/1/2017	6/5/2017	6/22/2017
2/13/2017	quarterly	$0.34	3.7%	2/28/2017	3/2/2017	3/20/2017
11/15/2016	quarterly	$0.34		12/1/2016	12/5/2016	12/20/2016
8/4/2016	quarterly	$0.34		8/18/2016	8/22/2016	9/8/2016
5/9/2016	quarterly	$0.34		5/20/2016	5/24/2016	6/7/2016
2/16/2016	Quarterly	$0.2890		2/25/2016	2/29/2016	3/14/2016
10/29/2015	quarterly	$0.34		11/13/2015	11/17/2015	12/3/2015
7/30/2015	quarterly	$0.34		8/18/2015	8/20/2015	9/3/2015
5/5/2015	special	$0.34	2.25%	5/15/2015	5/19/2015	6/4/2015
2/5/2015	quarterly	$0.34	2.36%	2/17/2015	2/19/2015	3/3/2015
10/31/2014	special	$0.3210	2.43%	11/13/2014	11/17/2014	12/2/2014
8/1/2014	quarterly	$0.3530	2.61%	8/19/2014	8/21/2014	9/4/2014
5/2/2014	quarterly	$0.3470	2.77%	5/16/2014	5/20/2014	6/2/2014
2/4/2014		$0.34		2/20/2014	2/24/2014	3/10/2014
11/1/2013	quarterly	$0.3260	3.51%	11/18/2013	11/20/2013	12/2/2013
8/5/2013	quarterly	$0.3220	3.34%	8/16/2013	8/20/2013	9/3/2013
8/1/2013	quarterly	$0.3220			8/20/2013	9/2/2013
5/6/2013	special	$0.32	3.28%	5/16/2013	5/20/2013	6/3/2013
2/8/2013	quarterly	$0.31	3.21%	2/19/2013	2/21/2013	3/7/2013

(Data available from 1/1/2013 forward)

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 58.20%

Insider Trading History for Teva Pharmaceutical Industries (NYSE:TEVA)

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2018	Deborah A Griffin	Insider	Sell	943	$17.88	$16,860.84
3/19/2018	Michael James Mcclellan	CFO	Sell	287	$17.88	$5,131.56
3/19/2018	Richard Daniell	VP	Sell	1,297	$17.89	$23,203.33	1,297
3/19/2018	Sven Dethlefs	EVP	Sell	571	$17.88	$10,209.48	5,016
3/5/2018	Brendan P O'grady	EVP	Sell	705	$19.38	$13,662.90
3/5/2018	Deborah A Griffin	Insider	Sell	773	$19.38	$14,980.74
3/5/2018	Richard Daniell	VP	Sell	1,108	$19.28	$21,362.24
2/15/2018	Mark Sabag	EVP	Sell	5,050	$19.68	$99,384.00	44,517

(Data available from 1/1/2013 forward)

Teva Pharmaceutical Industries (NYSE TEVA) News Headlines

Source:

Date	Headline
	A massive pharmaceutical middleman is taking aim at the price of a new group of migraine drugs www.businessinsider.com - April 24 at 5:46 PM
	Global Biosimilars Market Competitive landscape: Teva Pharmaceutical Industries Ltd., Mylan Inc. www.marketwatch.com - April 24 at 8:07 AM
	Teva Pharmaceutical Industries (TEVA) Given a $17.00 Price Target at Wells Fargo www.americanbankingnews.com - April 23 at 9:18 AM
	Teva Pharmaceutical Industries (TEVA) Expected to Post Quarterly Sales of $4.79 Billion www.americanbankingnews.com - April 23 at 4:52 AM
	MARKETS: Today's winning stocks are more interesting than the losers, like Procter & Gamble finance.yahoo.com - April 21 at 5:25 PM
	$0.68 EPS Expected for Teva Pharmaceutical Industries (TEVA) This Quarter www.americanbankingnews.com - April 21 at 3:14 AM
	P&G, Teva ending partnership www.bizjournals.com - April 20 at 5:34 PM
	Teva Pharmaceutical Industries (TEVA) Receives "Hold" Rating from Wells Fargo www.americanbankingnews.com - April 20 at 3:01 PM
	Mizuho Reaffirms Buy Rating for Teva Pharmaceutical Industries (TEVA) www.americanbankingnews.com - April 20 at 11:52 AM
	Global Cystic Fibrosis Therapeutics Market Overview 2017-2026: Teva Pharmaceutical Industries Ltd www.marketwatch.com - April 20 at 8:07 AM
	Teva Pharmaceutical Industries Ltd (TEVA) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - April 19 at 5:56 PM
	Teva, Procter & Gamble to dissolve OTC partnership. finance.yahoo.com - April 19 at 5:54 PM
	BidaskClub Lowers Teva Pharmaceutical Industries (TEVA) to Hold www.americanbankingnews.com - April 19 at 12:49 PM
	Active Pharmaceutical Ingredient (API) Market is is Forecast to Cross US$ 219.00 Billion By 2023 www.marketwatch.com - April 19 at 8:02 AM
	BRIEF-Teva And P&G Have Agreed To Terminate The PGT Healthcare Partnership www.reuters.com - April 19 at 8:02 AM
	Teva and the Procter & Gamble Company Have Agreed to Terminate the PGT Healthcare Partnership finance.yahoo.com - April 19 at 8:02 AM
	P&G sales, earnings per share climb finance.yahoo.com - April 19 at 8:02 AM
	Heritage Pharma Announces Executive Leadership Changes www.prnewswire.com - April 18 at 5:57 PM
	Novartis’s 1Q18 Estimates: Expectations for Sandoz finance.yahoo.com - April 18 at 8:03 AM
	Teva Pharmaceutical Industries Ltd Forecasted to Earn Q1 2018 Earnings of $0.63 Per Share (TEVA) www.americanbankingnews.com - April 18 at 7:40 AM
	AbbVie’s Imbruvica in 4Q17 and Fiscal 2017 finance.yahoo.com - April 17 at 8:07 AM
	Teva to Present New Data Across Multiple Therapeutic Areas at 70th Annual Meeting of the American Academy of Neurology finance.yahoo.com - April 17 at 8:07 AM
	FY2021 EPS Estimates for Teva Pharmaceutical Industries Ltd Lowered by Leerink Swann (TEVA) www.americanbankingnews.com - April 17 at 7:05 AM
	Jefferies Group Reiterates Hold Rating for Teva Pharmaceutical Industries (TEVA) www.americanbankingnews.com - April 16 at 12:37 PM
	UPDATE 1-Israeli unions warn Teva Pharm over plan to close Ashdod plant www.reuters.com - April 16 at 8:03 AM
	Who Blinks First, Teva Or Histadrut? seekingalpha.com - April 16 at 8:03 AM
	Teva Pharmaceutical Industries Ltd (TEVA) Short Interest Update www.americanbankingnews.com - April 16 at 3:03 AM
	Israeli unions warn Teva Pharm over plan to close Ashdod plant finance.yahoo.com - April 15 at 8:51 AM
	Oppenheimer Downgrades Teva Pharmaceutical Industries (TEVA) to Market Perform www.americanbankingnews.com - April 13 at 6:01 PM
	Teva Pharmaceutical Industries (TEVA) PT Set at $39.00 by Credit Suisse Group www.americanbankingnews.com - April 13 at 6:01 PM
	UBS Downgrades Teva Pharmaceutical Industries (TEVA) to Market Perform www.americanbankingnews.com - April 13 at 6:01 PM
	US appeals court strikes down Maryland drug price-gouging law www.reuters.com - April 13 at 5:47 PM
	Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Credit Suisse Group www.americanbankingnews.com - April 12 at 2:52 PM
	Teva Pharmaceutical Industries (TEVA) Stock Rating Reaffirmed by Cantor Fitzgerald www.americanbankingnews.com - April 12 at 2:19 PM
	Jefferies Group Reaffirms Hold Rating for Teva Pharmaceutical Industries (TEVA) www.americanbankingnews.com - April 11 at 7:53 PM
	Deutsche Bank Reaffirms Buy Rating for Teva Pharmaceutical Industries (TEVA) www.americanbankingnews.com - April 11 at 7:53 PM
	Teva Pharmaceutical Industries (TEVA) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 11 at 6:44 PM
	The Major Pharma Stocks That Are Making Short Sellers Sick www.msn.com - April 11 at 5:51 PM
	Are Drug Prices Too Low? finance.yahoo.com - April 11 at 8:07 AM
	Mylan to buy MS drug marketing rights from Israel's Mapi Pharma www.reuters.com - April 10 at 5:43 PM
	Teva Pharmaceutical’s Specialty Medicines Segment Performance finance.yahoo.com - April 10 at 8:09 AM
	Teva Pharmaceutical Industries' (TEVA) Neutral Rating Reiterated at Mizuho www.americanbankingnews.com - April 9 at 10:55 PM
	Teva Pharmaceutical Industries (TEVA) Downgraded to D+ at TheStreet www.americanbankingnews.com - April 9 at 7:30 PM
	Teva Pharm to close plant in Israel after no buyer found finance.yahoo.com - April 9 at 5:35 PM
	AssistRx co-founder: Why company took on Teva employees, lease in OP finance.yahoo.com - April 9 at 5:35 PM
	Teva Pharmaceutical Industries (TEVA) Upgraded to "Buy" by ValuEngine www.americanbankingnews.com - April 8 at 10:47 AM
	Analysts Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Announce Quarterly Sales of $4.77 Billion www.americanbankingnews.com - April 6 at 4:32 AM
	Teva Pharmaceutical Industries (TEVA) Given a $23.00 Price Target by Credit Suisse Group Analysts www.americanbankingnews.com - April 5 at 11:20 AM
	Teva Pharmaceutical Industries (TEVA) PT Set at $38.00 by Evercore ISI www.americanbankingnews.com - April 4 at 9:36 PM
	Teva, Valeant Exposed By California's Drug Transparency Law seekingalpha.com - April 4 at 4:27 PM

Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement

Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff